GeneDx Holdings (WGS) Cash from Financing Activities (2020 - 2026)

GeneDx Holdings (WGS) has reported Cash from Financing Activities for 7 consecutive years, with $1.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 190.46% year-over-year to $1.0 million in Q2 2026; TTM through Jun 2026 was $73.6 million, a 24.56% increase from a year earlier, with the FY2025 full-year figure at $48.0 million, up 8.75% from the prior year.
• Cash from Financing Activities was $1.0 million for Q2 2026 at GeneDx Holdings, down from $38.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $198.1 million in Q2 2022 and troughed at -$911000.0 in Q3 2023.
• A 5-year average of $28.6 million and a median of $9.1 million in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 83011.25% in 2023 and sank 105.29% in 2024, its largest moves.
• Over 5 years, Cash from Financing Activities stood at $65000.0 in 2022, then jumped by 72366.15% to $47.1 million in 2023, then tumbled by 34.14% to $31.0 million in 2024, then dropped by 25.24% to $23.2 million in 2025, then plunged by 95.67% to $1.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $1.0 million (Q2 2026), $38.6 million (Q1 2026), and $23.2 million (Q4 2025), per Business Quant data.